Lamassu BioTech

Progress in Action: Lamassu Biotech is building a brighter future for patients worldwide through the development of SA53-MDM2 therapy, currently in Phase 1 trials. Read more here: https://lnkd.in/ewgy-uzs #LamassuSA53

Innovation meets compassion. Lamassu Biotech is advancing treatments with a patient-first approach. Our research today is transforming lives tomorrow. Learn more at LamassuBio.com.

Meet the minds behind the mission. At Lamassu Biotech, our dedicated team of scientists, researchers, and innovators work tirelessly to redefine patient care. Learn more about what drives us. “We are excited by bringing something to the patient. And that’s our expertise. We understand the research. We understand patients,” said Gabi Hanna MD., CEO and Founder of Lamassu. Read more from the Cleveland Plains Dealer here: https://lnkd.in/e8tGp4sX.

Pioneering therapies for a better tomorrow. At Lamassu Biotech, we’re breaking barriers in patient care through innovation and science. Together, let’s transform lives. Learn more at lamassubio.com.

Bridging the Gap: Lamassu is revolutionizing drug development by leveraging innovative strategies to bridge academia and industry. Our talented team identifies novel therapeutics with strong scientific rationale and preclinical efficacy, ensuring a faster path to market approval. Together, we bring hope to patients waiting for life-saving treatments. Learn more at www.LamassuBioTech.com.  #TranslationalResearch #MedicalBreakthroughs

Lamassu BioTech is accelerating hope and healing. A private clinical stage company focusing on accelerating treatment, Lamassu’s team of dedicated physicians, researchers, and translational scientists are driven by a passion to treat patients like family. Follow #LamassuBioTech today using @LamassuBioTech on LinkedIn, Facebook, Instagram and Twitter.

#ThrowbackThursday - Earlier this year, in an exclusive column for cleveland.com, Lamassu Biotech CEO Gabi Hanna MD., wrote: "Few challenges loom larger for humanity than the fight against cancer. Cancer is an adversary that demands an approach that harnesses the latest technology and the best instincts of the human spirit – on a global scale. By leveraging the collective expertise of researchers, clinicians, policymakers, and industry leaders, we can usher in a new era of hope and healing for cancer patients worldwide." #cancer #biotech #innovation #publicprivatepartnerships #cancertreatment #sarcoma #medicine

Successful biotechnology and pharmaceutical companies require a comprehensive approach to identifying and advancing solutions to unmet needs in the healthcare market. Lamassu is privileged to have built strong relationships with some of the most accomplished and iconic brands and institutions in biotech.  #biotech #drugdevelopment #research #clinicaltrials #cancer #pancreatitis

Acute pancreatitis is a leading cause of emergency department visits and gastrointestinal admissions in the United States. For patients suffering from this condition, this results in many hospitalizations, ineffective medications, long term complications, and lost time with their families and at work. Lamassu’s lead candidate, RABI-767, is a novel small molecule therapy for acute pancreatitis. It was developed at the Mayo Clinic by leading scientists, and has profound preclinical efficacy to completely mitigate mortality and morbidity associated with severe acute pancreatitis. Phase 1/2 trials are currently ongoing. #pancreatitis #research #drugdevelopment #healthcare

Lamassu BioTech is accelerating hope and healing. A private clinical stage company focusing on accelerating treatment, Lamassu’s team of dedicated physicians, researchers, and translational scientists are driven by a passion to treat patients like family. Follow #LamassuBioTech today using @LamassuBioTech on LinkedIn, Facebook, Instagram and Twitter.